This message was sent to ##Email##
|
|
|
|
|
AST
With the growing concern about the Coronavirus (COVID-19), the AST has published FAQ pages and other resources for both professionals and patients.
READ MORE
AST
On April 17, a special module on donor and transplant issues was recorded. This recording can be found on the AST YouTube channel.
AST
Information regarding COVID-19 is changing rapidly. This document will be updated with the evolving issues related to medication access and drug shortages/supply chain issues within the United States of America during the pandemic.
AST
It is with great regret that we inform you the in-person ATC in Philadelphia must be canceled. We thank all of you for your patience and understanding while we have evaluated the status of ATC 2020. To view the full status on ATC 2020 and FAQ's, click here.
We are diligently working to transform our in-person program to ATC 2020’s Virtual Program that will showcase the latest research and advances made by the transplant community over the past year. More information will be provided on this in the coming weeks.
READ MORE
 |
|
Promoted by
Veloxis Pharmaceuticals
Now you can see the different ways that different formulations are released and absorbed in the gastrointestinal system. You’ll also have the opportunity to explore comparative pharmacokinetic results in rapid metabolizers, efficacy data over 2 years, and safety information.
Watch Video
|
|
AST
CareDx, Inc., in collaboration with the AST Research Network, is seeking proposals for "Utility of Donor Derived Cell Free DNA."
The submission deadline has been extended to June 19, 2020, to support the needs of transplant professionals during the COVID-19 pandemic. The start of the grant term will remain October 1, 2020.
READ MORE
Veloxis Pharmaceuticals
 Explore this phase 3 randomized, double-blind, double-dummy, multicenter, multinational, non-inferiority trial published in the American Journal of Transplantation. The study examined treatment failures defined as BPAR, graft failure, death, and delayed graft
function at 3 months and 12 months.
READ MORE
AST
Like most non-profit organizations, the AST has many valuable relationships that contribute to its continued growth and sustainability. To give our partners the opportunity to showcase their current initiatives and news, the AST posted its April 2020 Partner's Blog.
READ MORE
|
|
AST
The Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act would extend Medicare coverage of immunosuppressive drugs for kidney transplant recipients, which is currently limited to just 36 months. Please take a moment to contact your Members of Congress about this important legislation. Contact Congress Today
AST
Transplant professionals have increasing demands on their time. Finding time in one’s day to attend conferences or to read journals is challenging. Transplant in 10 is intended to provide transplant professionals with short, easily accessible videos on key and updated topics in 10 minutes.
READ MORE
|
TruGraf® - The 1st and only non-invasive test to rule out “silent" subclinical rejection in stable kidney transplant recipients
The only test to be reimbursed as an alternative to surveillance biopsies
Developed by Clinicians for Clinicians
Learn More
|
|
|
|
|
Reach Your Prospects Every Week
Thousands of industry professionals subscribe to association news briefs, which allows your company to push messaging directly to their inboxes and take advantage of the association's brand affinity.
Connect with Highly Defined Buyers and Maximize Your Brand Exposure
|
|
|
|
|
| Upcoming Education Events
|
    |
AST
The survival advantage of pancreas after kidney transplant
May 4, 2020 | 2 pm ET | Online Activity
For more information, click here.
Signaling through the Inhibitory Fc Receptor FcgRIIB Induces CD8+ T Cell Apoptosis to Limit T Cell Immunity
May 19, 2020 | 2 pm ET | Online Activity
For more information, click here.
SHCV NAT+/- in Abdominal Organ Transplantation: Where Are We Now and What's Next?
May 27, 2020 | 2 pm ET | Online Activity
For more information, click here.
|
Promoted by
|
|
|
|
 |
Therapeutic Drug Monitoring
COVID-19 is a novel infectious disease caused by the severe acute respiratory distress (SARS)-corona virus-2 (SARS-CoV-2). Several therapeutic options are currently emerging but none with universal consensus or proven efficacy. Solid organ transplant recipients are perceived to be at increased risk of severe COVID-19 because of their immunosuppressed conditions due to chronic use of immunosuppressive drugs. It is therefore likely that solid organ transplant recipients will be treated with these experimental antivirals.
READ MORE
|
|
Hepatology
The goals of this document are to provide data on what is currently known about COVID‐19, and how it may impact hepatologists and liver transplant providers and their patients. Our aim is to provide a template for the development of clinical recommendations and policies to mitigate the impact of the COVID‐19 pandemic on liver patients and healthcare providers.
READ MORE
The Journal of Heart and Lung Transplantation
Thoracic donor procurement is a multi-faceted surgery that involves the coordination of a multidisciplinary effort involving a series of technical and logistical maneuvers between multiple recipient hospitals and teams. Currently, thoracic donor procurement and preservation varies widely between geographical regions and even among procurement teams within a hospital. This paper is an international effort to draw consensus pertaining to donor heart and lung procurement. We seek to proffer a means of standardization of the thoracic organ procurement.
READ MORE
The Journal of Heart and Lung Transplantation
Chronic lung allograft dysfunction (CLAD), the primary cause of poor outcome after lung transplantation, arises from fibrotic remodeling of the allograft and presents as diverse clinical phenotypes with variable courses. Here, we investigate if bronchoalveolar lavage (BAL) mesenchymal cell activity at CLAD onset can inform regarding disease phenotype, progression and survival.
READ MORE
American Journal of Transplantation
Transplant programs are being scaled back as healthcare systems worldwide respond to COVID‐19. Most centers are now taking only super urgent and urgent cases, if at all. Management of donor organs is also impacted. Contingency protocols may prioritize distance over equitable sharing principles. Live and deceased donation is either being selectively paused or operating under stringent criteria based on local capacity. This will inevitably lead to variable patient experience.
READ MORE
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
